Innovent Biologics, Inc. (INNOVENT BIO, 1801.HK) is listed on HKEX. The latest available quote update was captured at 2026-03-26 10:40:17.0.
Quote Snapshot
- Last Price: 79.400 HKD
- Day Change: -3.150 (-3.82%)
- Open: 82.550 HKD
- High: 83.500 HKD
- Low: 79.200 HKD
- Previous Close: 82.550 HKD
- Volume: 8.01 M
- Market Cap: 137.77 B
- P/E Ratio: N/A
- Dividend Yield: N/A
- Board Lot: 500
- ISIN: KYG4818G1010
- Industry: Healthcare - Pharmaceuticals & Biotechnology
Company Overview
Innovent Biologics Inc is an investment holding company principally engaged in the research, development, production and sales of innovative medicines for the treatment of diseases such as cancer, cardiovascular and metabolic (CVM), autoimmune and eye diseases. The pipeline covering monoclonal antibodies, multi-specific antibodies, immuno-cytokine, antibody-drug conjugates (ADCs), cell therapy and small molecules. The Company’s main products include TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), Pemazyre (pemigatinib) and others. The Company mainly conducts its businesses within domestic and overseas markets.
Risk & Return Metrics
Based on 490 trading days of close price data (daily returns, annualized using 252 trading days).
| Metric | Daily | Annualized |
|---|---|---|
| Expected Return | 0.2156% | 72.06% |
| Risk (Std Dev) | 3.4633% | 54.98% |
| Metric | Value |
|---|---|
| First Price (HKD) | 38.550 |
| Last Price (HKD) | 82.550 |
| Total Return | 114.14% |